Pelabresib

A BET inhibitor used in cancer treatment

Pelabresib
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Pelabresib is a small molecule inhibitor of the bromodomain and extra-terminal motif (BET) family of proteins. It is being investigated for its potential use in the treatment of various types of cancer, including myelofibrosis and other hematological malignancies.

Mechanism of Action

Pelabresib functions by inhibiting the activity of BET proteins, which are epigenetic regulators that play a crucial role in the transcription of genes involved in cell cycle progression and apoptosis. BET proteins, such as BRD2, BRD3, and BRD4, recognize acetylated lysine residues on histone tails, facilitating the recruitment of transcriptional machinery to chromatin. By inhibiting these interactions, pelabresib disrupts the expression of oncogenes and other genes critical for cancer cell survival and proliferation.

Clinical Development

Pelabresib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with various cancers. Early-phase studies have shown promising results, particularly in the treatment of myelofibrosis, a type of chronic leukemia characterized by the replacement of bone marrow with fibrous tissue. In these studies, pelabresib has demonstrated the ability to reduce spleen size and improve symptoms in patients.

Pharmacokinetics

The pharmacokinetic profile of pelabresib includes its absorption, distribution, metabolism, and excretion characteristics. It is administered orally and has been shown to have a favorable bioavailability. The drug is metabolized primarily in the liver, and its metabolites are excreted via the urine and feces. The half-life of pelabresib allows for once-daily dosing, which is convenient for patients.

Side Effects

Common side effects observed in clinical trials of pelabresib include fatigue, nausea, diarrhea, and thrombocytopenia. These adverse effects are generally manageable with supportive care and dose adjustments. Serious adverse events are rare but may include liver function abnormalities and hematological toxicities.

Research and Future Directions

Ongoing research is focused on understanding the full therapeutic potential of pelabresib in combination with other anticancer agents. Studies are exploring its use in combination with JAK inhibitors and other targeted therapies to enhance its efficacy and overcome resistance mechanisms. Additionally, research is being conducted to identify biomarkers that can predict response to pelabresib treatment, which would allow for more personalized therapy approaches.

Related Pages

• Bromodomain and extra-terminal motif
• Myelofibrosis
• Cancer treatment
• Epigenetics